The expected EPS of $0.65 sets a benchmark for Novo Nordisk's performance. Historical stock reactions to earnings have been mixed, indicating that the upcoming report could lead to either a positive or negative short-term impact. The stock's strong year-to-date performance may lead to optimistic expectations, but as guidance is a significant factor, the actual impact will depend on whether the company can exceed expectations and provide positive future guidance.